Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters

Atherosclerosis. 2011 Jan;214(1):86-93. doi: 10.1016/j.atherosclerosis.2010.10.033. Epub 2010 Nov 2.

Abstract

Background: Fenofibrate, a PPAR-α agonist and rosiglitazone, a PPAR-γ agonist, reduce triglycerides and fatty acids in humans and in animal disease models. The efficacy of PPAR-α agonists in mouse model of human atherosclerosis disease has shown mixed results, and efficacy of PPAR-γ and liver X receptor (LXR) agonists has not been evaluated in cholesterol ester transfer protein (CETP) producing animal models.

Methods and results: The efficacy of PPAR-α, PPAR-γ and LXR agonists on lipid lowering and antiatherosclerotic activities was studied in atherosclerosis-susceptible F(1)B hamster that showed greater responsiveness to dietary fat and cholesterol (HFHC) diet and increased severity of atherosclerosis compared to Golden Syrian (GS) hamsters (aortic lesion 0.3% in GS vs 5% in F(1)B). F(1)B hamsters were fed HFHC diet and simultaneously treated with fenofibrate, rosiglitazone, and T0901317 (a pan LXR agonist) for 8 weeks. Fenofibrate lowered triglycerides and LDL-C by >80%, rosiglitazone did not significantly impact plasma lipid levels, and as expected, T0901317 increased triglycerides by 3-fold and HDL-C by 50%. The lesions in the aortic arch area as measured by en face method, decreased by 81%, 38% and 35%, following fenofibrate, rosiglitazone, and T0901317 treatments, respectively. In F(1)B hamster regression model, fenofibrate decreased levels of triglycerides and LDL-C by >85%, and LDL-C by >70%, respectively, which resulted in ∼50% regression of aortic lesions compared to vehicle treated group, and ∼36% compared to baseline.

Conclusions: These results demonstrate that: (a) F(1)B hamster is more sensitive to developing diet-induced hyperlipidemia and atherosclerosis; and (b) the greater antiatherosclerotic efficacy of fenofibrate occurred primarily via reductions in proatherogenic lipoproteins. Thus, PPAR-α selective agonist shows a greater anti-atherosclerotic response compared to PPAR-γ and LXR agonists in diet-induced atherosclerosis-susceptible F(1)B hamster.

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology
  • Atherosclerosis / drug therapy*
  • Atherosclerosis / metabolism*
  • Cholesterol / metabolism
  • Cricetinae
  • Fatty Acids / metabolism
  • Female
  • Fenofibrate / pharmacology
  • Hydrocarbons, Fluorinated / pharmacology
  • Hyperlipidemias / drug therapy*
  • Hyperlipidemias / metabolism*
  • Liver X Receptors
  • Male
  • Mesocricetus
  • Orphan Nuclear Receptors / metabolism*
  • PPAR alpha / metabolism*
  • PPAR gamma / metabolism*
  • Rosiglitazone
  • Sulfonamides / pharmacology
  • Thiazolidinediones / pharmacology
  • Triglycerides / metabolism

Substances

  • Anticholesteremic Agents
  • Fatty Acids
  • Hydrocarbons, Fluorinated
  • Liver X Receptors
  • Orphan Nuclear Receptors
  • PPAR alpha
  • PPAR gamma
  • Sulfonamides
  • T0901317
  • Thiazolidinediones
  • Triglycerides
  • Rosiglitazone
  • Cholesterol
  • Fenofibrate